Goldman Sachs Group Inc. Acquires 322,353 Shares of TransMedics Group, Inc. $TMDX

Goldman Sachs Group Inc. increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 50.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 965,931 shares of the company’s stock after purchasing an additional 322,353 shares during the quarter. Goldman Sachs Group Inc. owned 2.83% of TransMedics Group worth $117,506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Norges Bank bought a new position in shares of TransMedics Group during the fourth quarter valued at $3,719,000. Eurizon Capital SGR S.p.A. bought a new position in TransMedics Group in the fourth quarter valued at about $80,000. Foundations Investment Advisors LLC lifted its holdings in TransMedics Group by 60.4% in the fourth quarter. Foundations Investment Advisors LLC now owns 4,182 shares of the company’s stock valued at $509,000 after acquiring an additional 1,575 shares during the period. Geode Capital Management LLC lifted its holdings in TransMedics Group by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after acquiring an additional 2,903 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its holdings in TransMedics Group by 70.5% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 2,636 shares of the company’s stock valued at $321,000 after acquiring an additional 1,090 shares during the period. 99.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on TMDX shares. Canaccord Genuity Group lowered their target price on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. TD Cowen reduced their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Piper Sandler reduced their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Needham & Company LLC reduced their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $134.00.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $71.14 on Tuesday. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The stock has a 50-day moving average price of $88.16 and a 200 day moving average price of $116.65. The stock has a market capitalization of $2.46 billion, a P/E ratio of 16.17 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the prior year, the business posted $0.70 EPS. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.